Novartis, Genentech Suffer Blow In Asthma Drug Patent Feud
Pharmaceutical giants Novartis and Genentech lost their bid at a European patent court to preemptively stop Celltrion from releasing its rival asthma drug to the European market Friday, as the rivals...To view the full article, register now.
Already a subscriber? Click here to view full article